Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisugabalin for bortezomib-induced chemotherapy-induced peripheral neuropathy
ChiCTR2600133212Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of crisugabalin besilate in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Change from baseline in pain numerical rating scale. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ChiCTR2600133212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133212.